146 related articles for article (PubMed ID: 3270086)
1. Growth hormone, body composition and somatomedin C after treatment of acromegaly.
McLellan AR; Connell JM; Beastall GH; Teasdale G; Davies DL
Q J Med; 1988 Dec; 69(260):997-1008. PubMed ID: 3270086
[TBL] [Abstract][Full Text] [Related]
2. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of acromegaly by radioimmunoassay of somatomedin-C.
Clemmons DR; Van Wyk JJ; Ridgway EC; Kliman B; Kjellberg RN; Underwood LE
N Engl J Med; 1979 Nov; 301(21):1138-42. PubMed ID: 492275
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone, insulin-like growth factor-I and its binding proteins in the follow-up of acromegaly.
Wass JA
J Endocrinol; 1997 Oct; 155 Suppl 1():S17-9; discussion S21. PubMed ID: 9389991
[TBL] [Abstract][Full Text] [Related]
5. [What is the value of determining immunoreactive GHRH in acromegaly?].
Müller B; de Marco D; Bürgi U; Mullis PE
Schweiz Med Wochenschr; 1999 Aug; 129(33):1152-61. PubMed ID: 10483668
[TBL] [Abstract][Full Text] [Related]
6. Discrepancies between bioassayable somatomedin activity and somatomedin C levels in acromegalic patients.
Jasper HG; Artese R; Molocznik I; Bruno O
Medicina (B Aires); 1986; 46(4):440-4. PubMed ID: 3574106
[No Abstract] [Full Text] [Related]
7. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
Colao A; Pivonello R; Cavallo LM; Gaccione M; Auriemma RS; Esposito F; Cappabianca P; Lombardi G
Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
[TBL] [Abstract][Full Text] [Related]
8. Detection of colorectal lesions by using autofluorescence colonoscopy in acromegalics and their relation to serum growth hormone and insulin-like growth factor-1 levels.
Matyja V; Kos-Kudla B; Foltyn W; Strzelczyk J; Latos W; Marek B; Kajdaniuk D; Karpe J; Ostrowska Z; Sieron-Stoltny K; Sieron A
Neuro Endocrinol Lett; 2006 Oct; 27(5):639-43. PubMed ID: 17159821
[TBL] [Abstract][Full Text] [Related]
9. [Radioimmunologic determination of growth factors. I. Determination of somatomedin C].
Borota R; Curić N; Babić L; Avramov J; Krajnović J
Med Pregl; 1989; 42(9-10):313-7. PubMed ID: 2699913
[TBL] [Abstract][Full Text] [Related]
10. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.
Gilbert JA; Miell JP; Chambers SM; McGregor AM; Aylwin SJ
Clin Endocrinol (Oxf); 2005 Jun; 62(6):742-7. PubMed ID: 15943838
[TBL] [Abstract][Full Text] [Related]
11. Somatomedin C in treated acromegaly: poor correlation with growth hormone and clinical response.
Stonesifer LD; Jordan RM; Kohler PO
J Clin Endocrinol Metab; 1981 Nov; 53(5):931-4. PubMed ID: 7197287
[TBL] [Abstract][Full Text] [Related]
12. Somatomedin-C in active and successfully treated acromegaly.
Knappe G; Hesse V; Jahreis G; Rohde W; Gerl H
Exp Clin Endocrinol; 1988 Mar; 91(1):2-6. PubMed ID: 3371416
[TBL] [Abstract][Full Text] [Related]
13. [The place of insulin-like growth factor I in the diagnosis of acromegaly].
Dohán O; Góth M; Szabolcs I; Kovács L; Kovács Z; Szilágyi G
Orv Hetil; 1993 Oct; 134(42):2301-3. PubMed ID: 8233444
[TBL] [Abstract][Full Text] [Related]
14. The insulin-like growth axis in patients with autoimmune thyrotoxicosis: effect of antithyroid drug treatment.
Zimmermann-Belsing T; Juul A; Juul Holst J; Feldt-Rasmussen U
Growth Horm IGF Res; 2004 Jun; 14(3):235-44. PubMed ID: 15125885
[TBL] [Abstract][Full Text] [Related]
15. Radioimmunoassayable serum somatomedin B in normal subjects and in patients with acromegaly and pituitary dwarfism: effects of human growth hormone therapy.
Wajchenberg BL; Liberman B; Gomes EN; Pieroni RR
Horm Metab Res; 1980 Oct; 12(10):516-9. PubMed ID: 7439876
[TBL] [Abstract][Full Text] [Related]
16. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
17. Body composition, blood pressure and the renin-angiotensin system in acromegaly before and after treatment.
Davies DL; Beastall GH; Connell JM; Fraser R; McCruden D; Teasdale GM
J Hypertens Suppl; 1985 Dec; 3(3):S413-5. PubMed ID: 2856753
[TBL] [Abstract][Full Text] [Related]
18. Somatomedin-C levels in treated and untreated patients with acromegaly.
Roelfsema F; Frölich M; Van Dulken H
Clin Endocrinol (Oxf); 1987 Feb; 26(2):137-44. PubMed ID: 3665113
[TBL] [Abstract][Full Text] [Related]
19. Immunoreactive somatomedin C/insulin-like growth factor I in urine from normal subjects, pituitary dwarfs, and acromegalics.
Yokoya S; Suwa S; Maesaka H; Tanaka T
Pediatr Res; 1988 Feb; 23(2):151-4. PubMed ID: 3353157
[TBL] [Abstract][Full Text] [Related]
20. [Cardiac function and the skin microcirculation in acromegaly].
Bach R; Leicht E; Langer HJ; Hartenstein R; Jung F; Berg G; Schätzer-Klotz D; Bonaventura K; Schieffer H; Weinges KF
Dtsch Med Wochenschr; 1992 Mar; 117(13):483-9. PubMed ID: 1532357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
